Skip to main content

Table 1 Clinical profile of patients followed at start of study

From: Insulin versus oral agents in the management of Cystic Fibrosis Related Diabetes: a case based study

Pt Age (yrs) Wt (kg) FEV1 (%) % HbA1c at Dx Rx Course (yrs) Clinical Data
I1 28 65.8 56 5.5 4 PI, LupusN, Deceased
I2 31 65.3 44 14.3 2 PI, Deceased
I3 13 41.9 57 9.3 4 PS
I4 33 54.3 18 10.0 2 PI, Deceased, RI*
I5 14 49.0 99 10.9 8 PI
I6 44 81.5 30 9.2 5 PI, Cor P, HTN, BPH
I7 24 53.0 57 7.3 3 PI, AIHS, RI
I8 21 70.5 93 9.8 10 PI
S1 29 75.5 71 7.1 1 PI
S2 17 33.6 33 8.1 2 PI, Deceased
S3 25 73.9 48 7.8 4 PI, Deceased
S4 33 97.5 83 6.3 1 PI, Bipolar, HTN
S5 18 49.7 30 6.6 1 PI, Deceased
M1I4 35 51.5 17 9.7 1 PI
M2 24 71.1 117 5.4 2 PI
M3I5 22 68.5 68 9.6 2 PI
M4 19 70.0 100 6.1 3 PI
M5 22 67.7 88 13.3 3 PI, Hepatic Cirrhosis
M6 15 41.8 85 8.9 5 PI
T1 29 58.0 47 13.3 2 PI
T2 20 44.4 23 5.1 1 PI
T3I6 49 85.5 29 9.2 2 PI, Cor P, HTN, BPH
T4I7 32 55.7 65 7.3 2 PI, AIHS, RI
T5S4 34 96.5 92 6.3 1 PI, Bipolar, HTN
T6 40 54.0 56 9.6 2 PI, Lupus, RI ABPA
  1. Pt, patient (subscripts identify patient number, e.g. M1I4 was the first patient started on metformin and the fourth patient started on insulin); Rx Course (Yrs), represents the number of years that a patient received consecutive therapy with a specific class of agent; Mon, months; I, insulin; S, sulfonylurea; M, metformin; T, thiazolidinediones, FEV1, forced expiratory volume at 1 second; HbA1c, percent glycosylated hemoglobin; PI, pancreatic insufficient; PS, pancreatic sufficient; LupusN, lupus with nephritis; RI, renal insufficiency; Cor P, cor pulmonale; HTN, hypertension; BPH, benign prostatic hypertrophy; AIHS, autoimmune hypersplenism; ABPS, allergic bronchopulmonary aspergillosis. *Patient was switched back to insulin when diagnosed with renal insufficiency.